EXV4:XETRA:XETRA-iShares STOXX Europe 600 Health Care UCITS ETF (DE) (EUR)

ETF | Others |

Last Closing

USD 105.22

Change

+1.36 (+1.31)%

Market Cap

USD 0.70B

Volume

0.06M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-12 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
JARI:XETRA Amundi Index Solutions - Amund..

-0.91 (-1.97%)

USD 100.65B
EUNL:XETRA iShares Core MSCI World UCITS ..

+0.61 (+0.61%)

USD 84.07B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

-0.51 (-2.11%)

USD 79.79B
AW15:XETRA UBS (Irl) ETF plc - MSCI Japan..

-0.12 (-0.89%)

USD 58.88B
FJPR:XETRA Fidelity Sustainable Research ..

-0.06 (-1.16%)

USD 44.90B
EXX7:XETRA iShares Nikkei 225 UCITS ETF (..

-0.20 (-0.85%)

USD 28.25B
SPYL:XETRA SPDR S&P 500 UCITS ETF USD Acc..

+0.12 (+0.93%)

USD 23.49B
PPFB:XETRA iShares Physical Gold ETC EUR

-0.11 (-0.19%)

USD 20.66B
XDEE:XETRA Xtrackers S&P 500 Equal Weight..

+0.12 (+1.20%)

USD 12.74B
EUN5:XETRA iShares Core Corporate Bond UC..

+0.07 (+0.06%)

USD 12.26B

ETFs Containing EXV4:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -2.75% 38% F 37% F
Dividend Return -16.59% 45% F 17% F
Total Return -19.35% 6% D- 7% C-
Trailing 12 Months  
Capital Gain -10.65% 9% A- 15% F
Dividend Return -14.20% 51% F 12% F
Total Return -24.85% 4% F 8% B-
Trailing 5 Years  
Capital Gain 13.08% 32% F 36% F
Dividend Return -11.56% 48% F 10% F
Total Return 1.52% 27% F 28% F
Average Annual (5 Year Horizon)  
Capital Gain 6.89% 53% F 54% F
Dividend Return 7.68% 56% F 55% F
Total Return 0.78% 67% D+ 44% F
Risk Return Profile  
Volatility (Standard Deviation) 9.14% 65% D 73% C
Risk Adjusted Return 83.96% 74% C 77% C+
Market Capitalization 0.70B 77% C+ 59% D-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:

There is nothing we particularly dislike